As the first biotech firm to hit the public market via an initial public offering in 2007, Molecular Insight Pharmaceuticals Inc. is bringing in about $70 million to fund ongoing development work on its radiotherapeutics in cancer and its upcoming pivotal study of a molecular imaging agent in heart disease. (BioWorld Today) Read More
